You are here:

MS in the media - 23 October 2015

Published on

These are links to recent news stories that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.

Tysabri trial for SPMS is negative

A trial of Tysabri (natalizumab) found it was no better at placebo at slowing the build up of disability in secondary progressive MS.  There was some effect on upper limb function and some people showed some benefit based on the established effects of the drug in relapsing MS (reduced relapses and new lesions). 

Source: Biogen press release
Source: Wall Street Journal

MS Trust link: Tysabri (natalizumab)

ECTRIMS round up

More coverage of the ECTRIMS conference that took place in early October.  This report mentions (briefly): Brain Health; ocrelizumab; minocycline; Lemtrada; progressive MS; thyroid-like hormone; nerve repair; mesenchymal stem cells; anti-LINGO; diet; gut microbiome; fatigue; muscle mass; depression; sleep; exercise; cognitive rehab; memory

Source: National MS Society (USA)

MS Trust link: MS Trust ECTRIMS round up

The cost of MS

Research about the financial impact of MS in Ireland says that the condition costs Irish society more than €429 million a year - about €46,900 per person with MS.  In this, the cost of managing relapses is almost €17 million.  On average, individuals with MS face direct costs (scans, doctors and hospital visits) of €17,103 as well as more indirect costs

Source: Irish Times

Athlete with MS

Kadeena Cox, the sprinter diagnosed with MS last year, has won gold in the IPC Athletics World Championships in Doha

Source: Daily Telegraph

Print this page